{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:08:31Z","timestamp":1787166511266,"version":"build-2736575974"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s12035-021-02438-2","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T18:03:59Z","timestamp":1622570639000},"page":"4178-4187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["The Effect of COVID-19 on NF-\u03baB and Neurological Manifestations of Disease"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7988-941X","authenticated-orcid":false,"given":"Don A.","family":"Davies","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4585-5286","authenticated-orcid":false,"given":"Aida","family":"Adlimoghaddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7884-9261","authenticated-orcid":false,"given":"Benedict C.","family":"Albensi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"issue":"7798","key":"2438_CR1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu F et al (2020) A new coronavirus associated with human respiratory disease in China. Nature 579(7798):265\u2013269","journal-title":"Nature"},{"issue":"7798","key":"2438_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798):270\u2013273","journal-title":"Nature"},{"issue":"7821","key":"2438_CR3","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","volume":"584","author":"EJ Williamson","year":"2020","unstructured":"Williamson EJ et al (2020) Factors associated with COVID-19-related death using OpenSAFELY. Nature 584(7821):430\u2013436","journal-title":"Nature"},{"key":"2438_CR4","doi-asserted-by":"crossref","unstructured":"Gao YM et al (2020) Cytokine storm syndrome in coronavirus disease 2019: A narrative review. J Intern Med","DOI":"10.1111\/joim.13144"},{"issue":"5","key":"2438_CR5","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.immuni.2020.04.003","volume":"52","author":"T Hirano","year":"2020","unstructured":"Hirano T, Murakami M (2020) COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. Immunity 52(5):731\u2013733","journal-title":"Immunity"},{"issue":"2","key":"2438_CR6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.14336\/AD.2020.0910","volume":"12","author":"A Adlimoghaddam","year":"2021","unstructured":"Adlimoghaddam A et al (2021) Nilotinib improves bioenergetic profiling in brain astroglia in the 3xTg mouse model of Alzheimer\u2019s disease. Aging Dis 12(2):441\u2013465","journal-title":"Aging Dis"},{"key":"2438_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.mito.2020.12.008","volume":"57","author":"A Adlimoghaddam","year":"2021","unstructured":"Adlimoghaddam A, Albensi BC (2021) The nuclear factor kappa B (NF-kappaB) signaling pathway is involved in ammonia-induced mitochondrial dysfunction. Mitochondrion 57:63\u201375","journal-title":"Mitochondrion"},{"issue":"2","key":"2438_CR8","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1128\/JVI.02576-13","volume":"88","author":"ML DeDiego","year":"2014","unstructured":"DeDiego ML et al (2014) Inhibition of NF-kappaB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. J Virol 88(2):913\u2013924","journal-title":"J Virol"},{"issue":"4","key":"2438_CR9","doi-asserted-by":"publisher","first-page":"a000034","DOI":"10.1101\/cshperspect.a000034","volume":"1","author":"A Oeckinghaus","year":"2009","unstructured":"Oeckinghaus A, Ghosh S (2009) The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 1(4):a000034","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"9","key":"2438_CR10","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/j.1745-7270.2005.00082.x","volume":"37","author":"QJ Liao","year":"2005","unstructured":"Liao QJ et al (2005) Activation of NF-kappaB by the full-length nucleocapsid protein of the SARS coronavirus. Acta Biochim Biophys Sin (Shanghai) 37(9):607\u2013612","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"2438_CR11","doi-asserted-by":"crossref","unstructured":"Bougakov D, Podell K, and Goldberg E (2020) Multiple neuroinvasive pathways in COVID-19. Mol Neurobiol","DOI":"10.1007\/s12035-020-02152-5"},{"issue":"7","key":"2438_CR12","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/s41591-020-0968-3","volume":"26","author":"A Gupta","year":"2020","unstructured":"Gupta A et al (2020) Extrapulmonary manifestations of COVID-19. Nat Med 26(7):1017\u20131032","journal-title":"Nat Med"},{"issue":"21","key":"2438_CR13","doi-asserted-by":"publisher","first-page":"11727","DOI":"10.1073\/pnas.2003138117","volume":"117","author":"J Shang","year":"2020","unstructured":"Shang J et al (2020) Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A 117(21):11727\u201311734","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7807","key":"2438_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","volume":"581","author":"J Shang","year":"2020","unstructured":"Shang J et al (2020) Structural basis of receptor recognition by SARS-CoV-2. Nature 581(7807):221\u2013224","journal-title":"Nature"},{"issue":"6485","key":"2438_CR15","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1126\/science.abb2762","volume":"367","author":"R Yan","year":"2020","unstructured":"Yan R et al (2020) Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367(6485):1444\u20131448","journal-title":"Science"},{"issue":"9","key":"2438_CR16","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1021\/acschemneuro.0c00172","volume":"11","author":"R Butowt","year":"2020","unstructured":"Butowt R, Bilinska K (2020) SARS-CoV-2: olfaction, brain infection, and the urgent need for clinical samples allowing earlier virus detection. ACS Chem Neurosci 11(9):1200\u20131203","journal-title":"ACS Chem Neurosci"},{"issue":"5","key":"2438_CR17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1124\/molpharm.120.000014","volume":"97","author":"N Kabbani","year":"2020","unstructured":"Kabbani N, Olds JL (2020) Does COVID19 infect the brain? If so, smokers might be at a higher risk. Mol Pharmacol 97(5):351\u2013353","journal-title":"Mol Pharmacol"},{"issue":"6","key":"2438_CR18","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1111\/j.1471-4159.2008.05723.x","volume":"107","author":"H Xia","year":"2008","unstructured":"Xia H, Lazartigues E (2008) Angiotensin-converting enzyme 2 in the brain: properties and future directions. J Neurochem 107(6):1482\u20131494","journal-title":"J Neurochem"},{"issue":"7","key":"2438_CR19","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1021\/acschemneuro.0c00122","volume":"11","author":"AM Baig","year":"2020","unstructured":"Baig AM et al (2020) Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci 11(7):995\u2013998","journal-title":"ACS Chem Neurosci"},{"key":"2438_CR20","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/j.wneu.2020.03.063","volume":"139","author":"W Xie","year":"2020","unstructured":"Xie W et al (2020) OIP5-AS1 attenuates microangiopathy in diabetic mouse by regulating miR-200b\/ACE2. World Neurosurg 139:e52\u2013e60","journal-title":"World Neurosurg"},{"key":"2438_CR21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.neuropharm.2015.12.026","volume":"105","author":"L Wang","year":"2016","unstructured":"Wang L et al (2016) Increasing brain angiotensin converting enzyme 2 activity decreases anxiety-like behavior in male mice by activating central Mas receptors. Neuropharmacology 105:114\u2013123","journal-title":"Neuropharmacology"},{"key":"2438_CR22","doi-asserted-by":"crossref","unstructured":"Lukiw WJ, Pogue A, and Hill JM (2020) SARS-CoV-2 infectivity and neurological targets in the brain. Cell Mol Neurobiol","DOI":"10.1007\/s10571-020-00947-7"},{"issue":"3","key":"2438_CR23","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s12015-020-09976-7","volume":"16","author":"H Ulrich","year":"2020","unstructured":"Ulrich H, Pillat MM (2020) CD147 as a target for COVID-19 treatment: suggested effects of azithromycin and stem cell engagement. Stem Cell Rev Rep 16(3):434\u2013440","journal-title":"Stem Cell Rev Rep"},{"issue":"4","key":"2438_CR24","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.bbrc.2020.09.042","volume":"533","author":"J Qiao","year":"2020","unstructured":"Qiao J et al (2020) The expression of SARS-CoV-2 receptor ACE2 and CD147, and protease TMPRSS2 in human and mouse brain cells and mouse brain tissues. Biochem Biophys Res Commun 533(4):867\u2013871","journal-title":"Biochem Biophys Res Commun"},{"issue":"1\u20132","key":"2438_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2016.12.012","volume":"168","author":"Q Zhang","year":"2017","unstructured":"Zhang Q, Lenardo MJ, Baltimore D (2017) 30 years of NF-kappaB: a blossoming of relevance to human pathobiology. Cell 168(1\u20132):37\u201357","journal-title":"Cell"},{"key":"2438_CR26","doi-asserted-by":"crossref","unstructured":"Hariharan A et al (2020) The role and therapeutic potential of NF-kappa-B pathway in severe COVID-19 patients. Inflammopharmacology","DOI":"10.1007\/s10787-020-00773-9"},{"issue":"10","key":"2438_CR27","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nri910","volume":"2","author":"Q Li","year":"2002","unstructured":"Li Q, Verma IM (2002) NF-kappaB regulation in the immune system. Nat Rev Immunol 2(10):725\u2013734","journal-title":"Nat Rev Immunol"},{"key":"2438_CR28","doi-asserted-by":"crossref","unstructured":"Liu T et al (2017) NF-kappaB signaling in inflammation. Signal Transduct Target Ther 2","DOI":"10.1038\/sigtrans.2017.23"},{"issue":"1","key":"2438_CR29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0006-8993(96)00310-1","volume":"735","author":"K Terai","year":"1996","unstructured":"Terai K, Matsuo A, McGeer PL (1996) Enhancement of immunoreactivity for NF-kappa B in the hippocampal formation and cerebral cortex of Alzheimer\u2019s disease. Brain Res 735(1):159\u2013168","journal-title":"Brain Res"},{"issue":"6","key":"2438_CR30","doi-asserted-by":"publisher","first-page":"a001651","DOI":"10.1101\/cshperspect.a001651","volume":"1","author":"T Lawrence","year":"2009","unstructured":"Lawrence T (2009) The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 1(6):a001651","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"2","key":"2438_CR31","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.virol.2009.09.023","volume":"395","author":"CW Day","year":"2009","unstructured":"Day CW et al (2009) A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology 395(2):210\u2013222","journal-title":"Virology"},{"issue":"1\u20132","key":"2438_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.virusres.2009.01.005","volume":"142","author":"SF Dosch","year":"2009","unstructured":"Dosch SF, Mahajan SD, Collins AR (2009) SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-kappaB pathway in human monocyte macrophages in vitro. Virus Res 142(1\u20132):19\u201327","journal-title":"Virus Res"},{"issue":"6","key":"2438_CR33","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.stem.2020.09.013","volume":"27","author":"J Huang","year":"2020","unstructured":"Huang J et al (2020) SARS-CoV-2 infection of pluripotent stem cell-derived human lung alveolar type 2 cells elicits a rapid epithelial-intrinsic inflammatory response. Cell Stem Cell 27(6):962-973 e7","journal-title":"Cell Stem Cell"},{"key":"2438_CR34","doi-asserted-by":"publisher","first-page":"110412","DOI":"10.1016\/j.mehy.2020.110412","volume":"146","author":"M Carcaterra","year":"2021","unstructured":"Carcaterra M, Caruso C (2021) Alveolar epithelial cell type II as main target of SARS-CoV-2 virus and COVID-19 development via NF-Kb pathway deregulation: a physio-pathological theory. Med Hypotheses 146:110412","journal-title":"Med Hypotheses"},{"issue":"1","key":"2438_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1124\/mi.2.1.22","volume":"2","author":"F D\u2019Acquisto","year":"2002","unstructured":"D\u2019Acquisto F, May MJ, Ghosh S (2002) Inhibition of nuclear factor kappa B (NF-B): an emerging theme in anti-inflammatory therapies. Mol Interv 2(1):22\u201335","journal-title":"Mol Interv"},{"key":"2438_CR36","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3389\/fimmu.2019.00705","volume":"10","author":"MG Dorrington","year":"2019","unstructured":"Dorrington MG, Fraser IDC (2019) NF-kappaB signaling in macrophages: dynamics, crosstalk, and signal integration. Front Immunol 10:705","journal-title":"Front Immunol"},{"issue":"3","key":"2438_CR37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s12026-020-09137-5","volume":"68","author":"D Birra","year":"2020","unstructured":"Birra D et al (2020) COVID 19: a clue from innate immunity. Immunol Res 68(3):161\u2013168","journal-title":"Immunol Res"},{"key":"2438_CR38","doi-asserted-by":"crossref","unstructured":"Ingraham NE et al (2020) Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review. Eur Respir J 56(1)","DOI":"10.1183\/13993003.00912-2020"},{"issue":"3","key":"2438_CR39","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jmii.2020.04.015","volume":"53","author":"CA Devaux","year":"2020","unstructured":"Devaux CA, Rolain JM, Raoult D (2020) ACE2 receptor polymorphism: susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. J Microbiol Immunol Infect 53(3):425\u2013435","journal-title":"J Microbiol Immunol Infect"},{"issue":"16","key":"2438_CR40","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1042\/CS20200904","volume":"134","author":"DS Battagello","year":"2020","unstructured":"Battagello DS et al (2020) Unpuzzling COVID-19: tissue-related signaling pathways associated with SARS-CoV-2 infection and transmission. Clin Sci (Lond) 134(16):2137\u20132160","journal-title":"Clin Sci (Lond)"},{"issue":"2","key":"2438_CR41","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/cvr\/cvq076","volume":"86","author":"AR Brasier","year":"2010","unstructured":"Brasier AR (2010) The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc Res 86(2):211\u2013218","journal-title":"Cardiovasc Res"},{"issue":"1","key":"2438_CR42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/ni748","volume":"3","author":"S Saccani","year":"2002","unstructured":"Saccani S, Pantano S, Natoli G (2002) p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat Immunol 3(1):69\u201375","journal-title":"Nat Immunol"},{"issue":"3","key":"2438_CR43","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1161\/01.HYP.0000256831.33459.ea","volume":"49","author":"JK Park","year":"2007","unstructured":"Park JK et al (2007) p38 mitogen-activated protein kinase inhibition ameliorates angiotensin II-induced target organ damage. Hypertension 49(3):481\u2013489","journal-title":"Hypertension"},{"issue":"9","key":"2438_CR44","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nri.2017.52","volume":"17","author":"SC Sun","year":"2017","unstructured":"Sun SC (2017) The non-canonical NF-kappaB pathway in immunity and inflammation. Nat Rev Immunol 17(9):545\u2013558","journal-title":"Nat Rev Immunol"},{"key":"2438_CR45","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.yjmcc.2020.05.007","volume":"144","author":"JM Grimes","year":"2020","unstructured":"Grimes JM, Grimes KV (2020) p38 MAPK inhibition: a promising therapeutic approach for COVID-19. J Mol Cell Cardiol 144:63\u201365","journal-title":"J Mol Cell Cardiol"},{"key":"2438_CR46","doi-asserted-by":"publisher","first-page":"102801","DOI":"10.1016\/j.ebiom.2020.102801","volume":"56","author":"JM Berthelot","year":"2020","unstructured":"Berthelot JM, Liote F (2020) COVID-19 as a STING disorder with delayed over-secretion of interferon-beta. EBioMedicine 56:102801","journal-title":"EBioMedicine"},{"key":"2438_CR47","doi-asserted-by":"crossref","first-page":"175628642091783","DOI":"10.1177\/1756286420917830","volume":"13","author":"HY Wang","year":"2020","unstructured":"Wang HY et al (2020) Potential neurological symptoms of COVID-19. Ther Adv Neurol Disord 13:1756286420917830","journal-title":"Ther Adv Neurol Disord"},{"issue":"8","key":"2438_CR48","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1001\/jamaneurol.2020.2125","volume":"77","author":"LS Politi","year":"2020","unstructured":"Politi LS, Salsano E, Grimaldi M (2020) Magnetic resonance imaging alteration of the brain in a patient with coronavirus disease 2019 (COVID-19) and Anosmia. JAMA Neurol 77(8):1028\u20131029","journal-title":"JAMA Neurol"},{"key":"2438_CR49","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.bbi.2020.04.066","volume":"87","author":"G De Santis","year":"2020","unstructured":"De Santis G (2020) SARS-CoV-2: A new virus but a familiar inflammation brain pattern. Brain Behav Immun 87:95\u201396","journal-title":"Brain Behav Immun"},{"key":"2438_CR50","doi-asserted-by":"crossref","unstructured":"Dube M et al (2018) Axonal transport enables neuron-to-neuron propagation of human coronavirus OC43. J Virol 92(17)","DOI":"10.1128\/JVI.00404-18"},{"issue":"5032","key":"2438_CR51","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1126\/science.1683005","volume":"254","author":"JC Smith","year":"1991","unstructured":"Smith JC et al (1991) Pre-Botzinger complex: a brainstem region that may generate respiratory rhythm in mammals. Science 254(5032):726\u2013729","journal-title":"Science"},{"issue":"5","key":"2438_CR52","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.celrep.2012.09.013","volume":"2","author":"T Burgold","year":"2012","unstructured":"Burgold T et al (2012) The H3K27 demethylase JMJD3 is required for maintenance of the embryonic respiratory neuronal network, neonatal breathing, and survival. Cell Rep 2(5):1244\u20131258","journal-title":"Cell Rep"},{"issue":"13","key":"2438_CR53","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1113\/JP279177","volume":"598","author":"YH Hsieh","year":"2020","unstructured":"Hsieh YH et al (2020) Brainstem inflammation modulates the ventilatory pattern and its variability after acute lung injury in rodents. J Physiol 598(13):2791\u20132811","journal-title":"J Physiol"},{"issue":"7","key":"2438_CR54","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s00701-020-04374-x","volume":"162","author":"L Zanin","year":"2020","unstructured":"Zanin L et al (2020) SARS-CoV-2 can induce brain and spine demyelinating lesions. Acta Neurochir (Wien) 162(7):1491\u20131494","journal-title":"Acta Neurochir (Wien)"},{"issue":"1","key":"2438_CR55","doi-asserted-by":"publisher","first-page":"E232","DOI":"10.1148\/radiol.2020201697","volume":"297","author":"SG Kandemirli","year":"2020","unstructured":"Kandemirli SG et al (2020) Brain MRI findings in patients in the intensive care Unit with COVID-19 infection. Radiology 297(1):E232\u2013E235","journal-title":"Radiology"},{"issue":"1","key":"2438_CR56","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/ane.13266","volume":"142","author":"A Whittaker","year":"2020","unstructured":"Whittaker A, Anson M, Harky A (2020) Neurological manifestations of COVID-19: a systematic review and current update. Acta Neurol Scand 142(1):14\u201322","journal-title":"Acta Neurol Scand"},{"key":"2438_CR57","doi-asserted-by":"publisher","first-page":"116832","DOI":"10.1016\/j.jns.2020.116832","volume":"413","author":"AA Asadi-Pooya","year":"2020","unstructured":"Asadi-Pooya AA, Simani L (2020) Central nervous system manifestations of COVID-19: a systematic review. J Neurol Sci 413:116832","journal-title":"J Neurol Sci"},{"issue":"6","key":"2438_CR58","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1001\/jamaneurol.2020.1065","volume":"77","author":"SJ Pleasure","year":"2020","unstructured":"Pleasure SJ, Green AJ, Josephson SA (2020) The spectrum of neurologic disease in the severe acute respiratory syndrome coronavirus 2 pandemic infection: neurologists move to the frontlines. JAMA Neurol 77(6):679\u2013680","journal-title":"JAMA Neurol"},{"issue":"6","key":"2438_CR59","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/jamaneurol.2020.1127","volume":"77","author":"L Mao","year":"2020","unstructured":"Mao L et al (2020) Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 77(6):683\u2013690","journal-title":"JAMA Neurol"},{"key":"2438_CR60","doi-asserted-by":"publisher","first-page":"116884","DOI":"10.1016\/j.jns.2020.116884","volume":"414","author":"GC Roman","year":"2020","unstructured":"Roman GC et al (2020) The neurology of COVID-19 revisited: a proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries. J Neurol Sci 414:116884","journal-title":"J Neurol Sci"},{"issue":"23","key":"2438_CR61","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1056\/NEJMc2008597","volume":"382","author":"J Helms","year":"2020","unstructured":"Helms J et al (2020) Neurologic features in severe SARS-CoV-2 infection. N Engl J Med 382(23):2268\u20132270","journal-title":"N Engl J Med"},{"issue":"3","key":"2438_CR62","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.bja.2020.06.013","volume":"125","author":"CM Roberts","year":"2020","unstructured":"Roberts CM et al (2020) COVID-19: a complex multisystem disorder. Br J Anaesth 125(3):238\u2013242","journal-title":"Br J Anaesth"},{"issue":"2","key":"2438_CR63","doi-asserted-by":"publisher","first-page":"E119","DOI":"10.1148\/radiol.2020201187","volume":"296","author":"N Poyiadji","year":"2020","unstructured":"Poyiadji N et al (2020) COVID-19-associated acute hemorrhagic necrotizing encephalopathy: imaging features. Radiology 296(2):E119\u2013E120","journal-title":"Radiology"},{"issue":"5","key":"2438_CR64","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(20)30109-5","volume":"19","author":"H Zhao","year":"2020","unstructured":"Zhao H et al (2020) Guillain-Barre syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol 19(5):383\u2013384","journal-title":"Lancet Neurol"},{"issue":"2","key":"2438_CR65","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3109\/13550289609146543","volume":"2","author":"JJ Houtman","year":"1996","unstructured":"Houtman JJ, Fleming JO (1996) Dissociation of demyelination and viral clearance in congenitally immunodeficient mice infected with murine coronavirus JHM. J Neurovirol 2(2):101\u2013110","journal-title":"J Neurovirol"},{"key":"2438_CR66","doi-asserted-by":"crossref","unstructured":"Alberti P et al (2020) Guillain-Barre syndrome related to COVID-19 infection. Neurol Neuroimmunol Neuroinflamm 7(4)","DOI":"10.1212\/NXI.0000000000000741"},{"issue":"1\u20132","key":"2438_CR67","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jns.2007.08.026","volume":"264","author":"M Eggert","year":"2008","unstructured":"Eggert M et al (2008) Changes in the activation level of NF-kappa B in lymphocytes of MS patients during glucocorticoid pulse therapy. J Neurol Sci 264(1\u20132):145\u2013150","journal-title":"J Neurol Sci"},{"key":"2438_CR68","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jneuroim.2018.04.002","volume":"320","author":"J Yan","year":"2018","unstructured":"Yan J et al (2018) Increased constitutive activation of NF-kappaB p65 (RelA) in peripheral blood cells of patients with progressive multiple sclerosis. J Neuroimmunol 320:111\u2013116","journal-title":"J Neuroimmunol"},{"key":"2438_CR69","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3389\/fimmu.2020.00391","volume":"11","author":"Y Zhou","year":"2020","unstructured":"Zhou Y et al (2020) Nuclear factor kappaB (NF-kappaB)-mediated inflammation in multiple sclerosis. Front Immunol 11:391","journal-title":"Front Immunol"},{"key":"2438_CR70","doi-asserted-by":"crossref","unstructured":"Capone F et al (2021) COVID-19 in multiple sclerosis patients treated with dimethyl fumarate. J Neurol","DOI":"10.1007\/s00415-021-10446-4"},{"key":"2438_CR71","doi-asserted-by":"crossref","unstructured":"Talan J (2020) COVID-19: neurologists in Italy to colleagues in US: look for poorly-defined neurologic conditions in patients with the coronavirus. Neurology Today","DOI":"10.1097\/01.NT.0000662096.35724.1f"},{"issue":"10","key":"2438_CR72","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2215-0366(20)30287-X","volume":"7","author":"A Varatharaj","year":"2020","unstructured":"Varatharaj A et al (2020) Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry 7(10):875\u2013882","journal-title":"Lancet Psychiatry"},{"key":"2438_CR73","doi-asserted-by":"crossref","unstructured":"Graham EL et al (2021) Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 \u201clong haulers\u201d. Ann Clin Transl Neurol","DOI":"10.1002\/acn3.51350"},{"key":"2438_CR74","doi-asserted-by":"crossref","unstructured":"Rass V et al (2021) Neurological outcome and quality of life three months after COVID-19: a prospective observational cohort study. Eur J Neurol","DOI":"10.1111\/ene.14803"},{"issue":"24","key":"2438_CR75","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1021\/acschemneuro.0c00725","volume":"11","author":"AM Baig","year":"2020","unstructured":"Baig AM (2020) Deleterious outcomes in long-hauler COVID-19: the effects of SARS-CoV-2 on the CNS in chronic COVID syndrome. ACS Chem Neurosci 11(24):4017\u20134020","journal-title":"ACS Chem Neurosci"},{"issue":"7825","key":"2438_CR76","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/d41586-020-02598-6","volume":"585","author":"M Marshall","year":"2020","unstructured":"Marshall M (2020) The lasting misery of coronavirus long-haulers. Nature 585(7825):339\u2013341","journal-title":"Nature"},{"key":"2438_CR77","doi-asserted-by":"publisher","first-page":"m1252","DOI":"10.1136\/bmj.m1252","volume":"368","author":"E Mahase","year":"2020","unstructured":"Mahase E (2020) Covid-19: what treatments are being investigated? BMJ 368:m1252","journal-title":"BMJ"},{"key":"2438_CR78","doi-asserted-by":"publisher","first-page":"114296","DOI":"10.1016\/j.bcp.2020.114296","volume":"183","author":"H Yousefi","year":"2021","unstructured":"Yousefi H et al (2021) Repurposing existing drugs for the treatment of COVID-19\/SARS-CoV-2 infection: a review describing drug mechanisms of action. Biochem Pharmacol 183:114296","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"2438_CR79","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.canlet.2013.08.045","volume":"342","author":"R Kariya","year":"2014","unstructured":"Kariya R et al (2014) HIV protease inhibitor Lopinavir induces apoptosis of primary effusion lymphoma cells via suppression of NF-kappaB pathway. Cancer Lett 342(1):52\u201359","journal-title":"Cancer Lett"},{"issue":"3","key":"2438_CR80","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ijc.23993","volume":"124","author":"MZ Dewan","year":"2009","unstructured":"Dewan MZ et al (2009) An HIV protease inhibitor, ritonavir targets the nuclear factor-kappaB and inhibits the tumor growth and infiltration of EBV-positive lymphoblastoid B cells. Int J Cancer 124(3):622\u2013629","journal-title":"Int J Cancer"},{"issue":"19","key":"2438_CR81","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao B et al (2020) A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 382(19):1787\u20131799","journal-title":"N Engl J Med"},{"issue":"9","key":"2438_CR82","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1093\/jac\/dkaa190","volume":"75","author":"S Baldelli","year":"2020","unstructured":"Baldelli S et al (2020) Lopinavir\/ritonavir in COVID-19 patients: maybe yes, but at what dose? J Antimicrob Chemother 75(9):2704\u20132706","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"2438_CR83","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/mc.23234","volume":"59","author":"NN Alraouji","year":"2020","unstructured":"Alraouji NN et al (2020) Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer. Mol Carcinog 59(9):1041\u20131051","journal-title":"Mol Carcinog"},{"issue":"1","key":"2438_CR84","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s40121-020-00373-8","volume":"10","author":"B Ruiz-Antoran","year":"2021","unstructured":"Ruiz-Antoran B et al (2021) Combination of tocilizumab and steroids to improve mortality in patients with severe COVID-19 infection: a Spanish, multicenter, cohort study. Infect Dis Ther 10(1):347\u2013362","journal-title":"Infect Dis Ther"},{"issue":"6","key":"2438_CR85","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1046\/j.1471-4159.2003.01623.x","volume":"84","author":"J Park","year":"2003","unstructured":"Park J et al (2003) Chloroquine induces activation of nuclear factor-kappaB and subsequent expression of pro-inflammatory cytokines by human astroglial cells. J Neurochem 84(6):1266\u20131274","journal-title":"J Neurochem"},{"issue":"3","key":"2438_CR86","first-page":"2436","volume":"15","author":"N Liang","year":"2018","unstructured":"Liang N et al (2018) Immunosuppressive effects of hydroxychloroquine and artemisinin combination therapy via the nuclear factor-kappaB signaling pathway in lupus nephritis mice. Exp Ther Med 15(3):2436\u20132442","journal-title":"Exp Ther Med"},{"key":"2438_CR87","doi-asserted-by":"crossref","unstructured":"Chen L, Z Z-Y, Fu J-G, Feng Z-P, Zhang S-Z, Han Q-Y (2020) Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study","DOI":"10.1101\/2020.06.19.20136093"},{"issue":"10","key":"2438_CR88","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s11427-020-1732-2","volume":"63","author":"B Yu","year":"2020","unstructured":"Yu B et al (2020) Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci China Life Sci 63(10):1515\u20131521","journal-title":"Sci China Life Sci"},{"key":"2438_CR89","doi-asserted-by":"crossref","unstructured":"Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D (2020) Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial","DOI":"10.1101\/2020.03.22.20040758"},{"issue":"6","key":"2438_CR90","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.7150\/ijbs.59547","volume":"17","author":"Y Chen","year":"2021","unstructured":"Chen Y et al (2021) Hydroxychloroquine\/chloroquine as therapeutics for COVID-19: truth under the mystery. Int J Biol Sci 17(6):1538\u20131546","journal-title":"Int J Biol Sci"},{"issue":"5\u20136","key":"2438_CR91","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000464136","volume":"23","author":"G Asadikaram","year":"2016","unstructured":"Asadikaram G et al (2016) Interferon-beta 1a modulates expression of RAGE but not S100A12 and nuclear factor-kappaB in multiple sclerosis patients. NeuroImmunoModulation 23(5\u20136):345\u2013351","journal-title":"NeuroImmunoModulation"},{"issue":"1","key":"2438_CR92","doi-asserted-by":"publisher","first-page":"8059","DOI":"10.1038\/s41598-021-86859-y","volume":"11","author":"I Alavi Darazam","year":"2021","unstructured":"Alavi Darazam I et al (2021) Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial. Sci Rep 11(1):8059","journal-title":"Sci Rep"},{"issue":"10","key":"2438_CR93","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1056\/NEJMoa2001191","volume":"382","author":"ML Holshue","year":"2020","unstructured":"Holshue ML et al (2020) First case of 2019 novel coronavirus in the United States. N Engl J Med 382(10):929\u2013936","journal-title":"N Engl J Med"},{"issue":"24","key":"2438_CR94","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","volume":"382","author":"J Grein","year":"2020","unstructured":"Grein J et al (2020) Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 382(24):2327\u20132336","journal-title":"N Engl J Med"},{"issue":"10","key":"2438_CR95","first-page":"1192","volume":"6","author":"Q Cai","year":"2020","unstructured":"Cai Q et al (2020) Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing) 6(10):1192\u20131198","journal-title":"Engineering (Beijing)"},{"issue":"27","key":"2438_CR96","doi-asserted-by":"publisher","first-page":"E756","DOI":"10.1503\/cmaj.200645","volume":"192","author":"Z Ye","year":"2020","unstructured":"Ye Z et al (2020) Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis. CMAJ 192(27):E756\u2013E767","journal-title":"CMAJ"},{"issue":"5234","key":"2438_CR97","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1126\/science.270.5234.286","volume":"270","author":"N Auphan","year":"1995","unstructured":"Auphan N et al (1995) Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270(5234):286\u2013290","journal-title":"Science"},{"issue":"8","key":"2438_CR98","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"Group RC","year":"2021","unstructured":"Group RC et al (2021) Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 384(8):693\u2013704","journal-title":"N Engl J Med"},{"key":"2438_CR99","doi-asserted-by":"publisher","first-page":"101844","DOI":"10.1016\/j.tmaid.2020.101844","volume":"37","author":"SK Patel","year":"2020","unstructured":"Patel SK et al (2020) Dexamethasone: a boon for critically ill COVID-19 patients? Travel Med Infect Dis 37:101844","journal-title":"Travel Med Infect Dis"},{"issue":"1","key":"2438_CR100","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13054-021-03537-1","volume":"25","author":"C Robba","year":"2021","unstructured":"Robba C et al (2021) Early effects of ventilatory rescue therapies on systemic and cerebral oxygenation in mechanically ventilated COVID-19 patients with acute respiratory distress syndrome: a prospective observational study. Crit Care 25(1):111","journal-title":"Crit Care"},{"issue":"12","key":"2438_CR101","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1093\/nar\/24.12.2236","volume":"24","author":"JR Matthews","year":"1996","unstructured":"Matthews JR et al (1996) Inhibition of NF-kappaB DNA binding by nitric oxide. Nucleic Acids Res 24(12):2236\u20132242","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"2438_CR102","doi-asserted-by":"publisher","first-page":"96","DOI":"10.35772\/ghm.2020.01034","volume":"2","author":"K Ito","year":"2020","unstructured":"Ito K et al (2020) Major ongoing clinical trials for COVID-19 treatment and studies currently being conducted or scheduled in Japan. Glob Health Med 2(2):96\u2013101","journal-title":"Glob Health Med"},{"issue":"1","key":"2438_CR103","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1038\/s41467-021-21825-w","volume":"12","author":"H Zhao","year":"2021","unstructured":"Zhao H et al (2021) Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2. Nat Commun 12(1):1517","journal-title":"Nat Commun"},{"issue":"Pt A","key":"2438_CR104","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ijbiomac.2020.09.204","volume":"165","author":"F Oroojalian","year":"2020","unstructured":"Oroojalian F et al (2020) Novel insights into the treatment of SARS-CoV-2 infection: an overview of current clinical trials. Int J Biol Macromol 165(Pt A):18\u201343","journal-title":"Int J Biol Macromol"},{"issue":"7","key":"2438_CR105","doi-asserted-by":"publisher","first-page":"4662","DOI":"10.1074\/jbc.M006206200","volume":"276","author":"KC Das","year":"2001","unstructured":"Das KC (2001) c-Jun NH2-terminal kinase-mediated redox-dependent degradation of IkappaB: role of thioredoxin in NF-kappaB activation. J Biol Chem 276(7):4662\u20134670","journal-title":"J Biol Chem"},{"key":"2438_CR106","doi-asserted-by":"crossref","unstructured":"Bauer SR et al (2020) What is the role of supplementation with ascorbic acid, zinc, vitamin D, or N-acetylcysteine for prevention or treatment of COVID-19? Cleve Clin J Med","DOI":"10.3949\/ccjm.87a.ccc046"},{"key":"2438_CR107","doi-asserted-by":"publisher","first-page":"104893","DOI":"10.1016\/j.neuint.2020.104893","volume":"142","author":"A Ali","year":"2021","unstructured":"Ali A et al (2021) Vitamin D exerts neuroprotection via SIRT1\/nrf-2\/ NF-kB signaling pathways against D-galactose-induced memory impairment in adult mice. Neurochem Int 142:104893","journal-title":"Neurochem Int"},{"key":"2438_CR108","doi-asserted-by":"crossref","unstructured":"Di Somma C et al (2017) Vitamin D and neurological diseases: an endocrine view. Int J Mol Sci 18(11)","DOI":"10.3390\/ijms18112482"},{"issue":"4","key":"2438_CR109","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s13167-017-0120-8","volume":"8","author":"P Koduah","year":"2017","unstructured":"Koduah P, Paul F, Dorr JM (2017) Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases. EPMA J 8(4):313\u2013325","journal-title":"EPMA J"},{"issue":"1","key":"2438_CR110","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s12967-020-02488-5","volume":"18","author":"Y Xu","year":"2020","unstructured":"Xu Y et al (2020) The importance of vitamin d metabolism as a potential prophylactic, immunoregulatory and neuroprotective treatment for COVID-19. J Transl Med 18(1):322","journal-title":"J Transl Med"},{"key":"2438_CR111","doi-asserted-by":"crossref","unstructured":"Kazemi A et al (2021) Association of vitamin D status with SARS-CoV-2 infection or COVID-19 severity: a systematic review and meta-analysis. Adv Nutr","DOI":"10.1093\/advances\/nmab012"},{"key":"2438_CR112","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.2147\/TCRM.S273700","volume":"16","author":"Z Shi","year":"2020","unstructured":"Shi Z, Puyo CA (2020) N-Acetylcysteine to combat COVID-19: an evidence review. Ther Clin Risk Manag 16:1047\u20131055","journal-title":"Ther Clin Risk Manag"},{"issue":"2\u20133","key":"2438_CR113","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S0014-5793(00)01464-2","volume":"472","author":"S Oka","year":"2000","unstructured":"Oka S et al (2000) N-acetylcysteine suppresses TNF-induced NF-kappaB activation through inhibition of IkappaB kinases. FEBS Lett 472(2\u20133):196\u2013202","journal-title":"FEBS Lett"},{"key":"2438_CR114","doi-asserted-by":"publisher","first-page":"105437","DOI":"10.1016\/j.phrs.2021.105437","volume":"166","author":"G Bjorklund","year":"2021","unstructured":"Bjorklund G et al (2021) The impact of glutathione metabolism in autism spectrum disorder. Pharmacol Res 166:105437","journal-title":"Pharmacol Res"},{"key":"2438_CR115","doi-asserted-by":"publisher","first-page":"109778","DOI":"10.1016\/j.mehy.2020.109778","volume":"140","author":"SF Assimakopoulos","year":"2020","unstructured":"Assimakopoulos SF, Marangos M (2020) N-acetyl-cysteine may prevent COVID-19-associated cytokine storm and acute respiratory distress syndrome. Med Hypotheses 140:109778","journal-title":"Med Hypotheses"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-021-02438-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-021-02438-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-021-02438-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T00:46:08Z","timestamp":1626309968000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-021-02438-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":115,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["2438"],"URL":"https:\/\/doi.org\/10.1007\/s12035-021-02438-2","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,1]]},"assertion":[{"value":"12 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All authors gave their consent for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Dr. Albensi previously held the Manitoba Dementia Research Chair and currently holds the Honorable Douglas and Patricia Everett, and Royal Canadian\u00a0Properties Limited Endowment Fund Chair. The research was funded by Canadian Institutes of Health Research (CIHR), grant No. PJT-162144, and the St.\u00a0Boniface Hospital Research Foundation, grant Nos. 1406\u20133216 and 1410\u20133216. Dr. Albensi is a Research Affiliate of the Centre on Aging at the University\u00a0of Manitoba.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}